Reha Junjhunwala's investments in stocks fell by 50% on Wednesday. Some trading applications showed a drop of up to 50%, but this decline was not due to a reduction in invested funds, but rather to corporate changes.
The reason for such a sharp drop was the distribution of an exclusive stock bonus (ex-bonus) across all Concord Biotech shares on Wednesday, according to previously announced corporate actions. This decision was linked to the announcement of a bonus issuance for relevant shareholders, which reflected in the sharp decrease in share price.
Concord informed the stock exchange documentation that the company's board of directors, at a meeting held on October 27, 2026, set November 4 as the record date. The purpose of this date is to determine shareholders' right to receive bonus shares at a ratio of 1:1, meaning one bonus share for every fully paid existing share. This condition is subject to regulatory approval.
This means that all relevant Concord Biotech shareholders will receive an additional share for each share they hold on the record date. The total number of shares held by all relevant shareholders will double, but the share price will be adjusted accordingly, which will not change the total invested value.
Concord Biotech shares closed on Tuesday at a price of 1229.90 rupees, and after the bonus share issuance adjustment, they opened on Wednesday at a price of 610 rupees. It is possible that some trading applications displayed the unadjusted price from the previous day, which created the impression of a 50-52% drop on the exchange.
After the split adjustment, Concord Biotech shares initially fell to 595 rupees at the beginning of the session, but on Wednesday, they recovered, rising by 4.8% to 623.65 rupees. Meanwhile, the company's total market capitalization approached 13,000 crore rupees. The shares decreased by 24% compared to the 52-week high reached in August 2026 at 807.03 rupees. Nevertheless, the current price is 26% higher compared to the 52-week low recorded in April 2026 at 493.53 rupees.
Concord Biotech Limited, founded in 1984, is a biopharmaceutical company engaged in research and development in India and is among the country's leading API companies. Concord Biotech shares were first listed in August 2023 when the company raised 1,550.52 crore rupees at a price of 741 rupees per share. Currently, the shares are trading 70% above their adjusted IPO price.
Three discretionary trusts established in honor of the children of the late prominent investor Rakesh Junjhunwala own approximately 2.52 crore shares of the company (or 5.04 crore shares based on post-adjustment), representing a 24.10% stake. The value of this stake is currently estimated at 3,143.10 crore rupees.



